| Effect of Pycnogenol on the Healing of Venous Ulcers 2017 · Group 1 · Adults with venous ulcers | 150 mg | 90 days | 15 |
| Treatment of osteoarthritis with Pycnogenol. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of signs, symptoms, physical performance and vascular aspects 2008 · Treatment group · Patients with osteoarthritis; age and sex range not reported | 100 mg | 90 days | 77 |
| Impact of a Dietary Supplementation with French Maritime Pine Bark Extract Pycnogenol(®) on Salivary and Serum Inflammatory Biomarkers During Non-Surgical Periodontal Therapy-A Randomized Placebo-Controlled Double-Blind Trial 2025 · Pycnogenol® group · Adults aged 35–85 with gingival inflammation (at least 10% bleeding on probing), BMI 20–30 kg/m², and at least 10 natural teeth | 200 mg | 90 days | 46 |
| Treatment of vascular retinopathies with Pycnogenol 2001 · Pycnogenol · Patients with diabetes, atherosclerosis, or other vascular diseases involving the retina | 150 mg | 60 days | 30 |
| Oral administration of French maritime pine bark extract (Flavangenol(®)) improves clinical symptoms in photoaged facial skin 2012 · high-dose PBE trial · Healthy women aged 31–59 with age spots and mild-to-moderate facial photodamage | 100 mg | 12 weeks | 24 |
| Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study 2012 · Pycnogenol treatment · Adults with coronary artery disease (CAD); age and sex not specified | 200 mg | 8 weeks | 23 |
| A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Curcumin (Curcuma longa), Boswellia (Boswellia serrata), and French Maritime Pine Bark (Pinus pinaster) 2021 · lower-dose maritime pine · Men aged 47–65 with Gulf War Illness, excluding those with prediabetes, diabetes evidence, or diabetic medication use | 200 mg | 30 days | 10 |
| A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Curcumin (Curcuma longa), Boswellia (Boswellia serrata), and French Maritime Pine Bark (Pinus pinaster) 2021 · higher-dose maritime pine · Men aged 47–65 with Gulf War Illness, excluding those with prediabetes, diabetes evidence, or diabetic medication use | 400 mg | 30 days | 10 |
| Pycnogenol, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans 2007 · Pycnogenol · Healthy young men | 180 mg | 2 weeks | 8 |
| Pycnogenol in chronic venous insufficiency 2000 · Pycnogenol · Patients with chronic venous insufficiency and leg varices | 300 mg | 60 days | — |
| Comparative study of Venostasin and Pycnogenol in chronic venous insufficiency 2002 · Pycnogenol · Patients with diagnosed chronic venous insufficiency; age and sex not reported | 360 mg | 4 weeks | — |
| A randomised, double-blind, placebo-controlled trial on the effect of Pycnogenol on the climacteric syndrome in peri-menopausal women 2007 · Pycnogenol · Peri-menopausal women with climacteric symptoms | 200 mg | — | — |
| Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis 2008 · Pycnogenol · Patients with stage I or II knee osteoarthritis | 150 mg | 90 days | — |
| Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol: a prospective, controlled study 2010 · group treated with Pycnogenol only · Adults with symptomatic chronic venous insufficiency and edema | 150 mg | 8 weeks | — |
| Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol: a prospective, controlled study 2010 · group treated with both Pycnogenol and elastic stockings · Adults with symptomatic chronic venous insufficiency and edema | 150 mg | 8 weeks | — |
| French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double-blind, randomized, placebo-controlled trial 2021 · Pycnogenol (PYC) · Women with facial melasma; age range not reported | 150 mg | 60 days | — |
| Effect of low-dose French maritime pine bark extract on climacteric syndrome in 170 perimenopausal women: a randomized, double-blind, placebo-controlled trial 2013 · Pycnogenol group · Perimenopausal women | 60 mg | 90 days | 85 |
| Pycnogenol supplementation as an adjunct treatment for antidepressant-induced sexual dysfunction 2019 · ESC + PYC group · Outpatients of both genders with depression receiving escitalopram and experiencing antidepressant-induced sexual dysfunction | 50 mg | 120 days | 37 |
| French maritime pine bark extract significantly lowers the requirement for analgesic medication in dysmenorrhea: a multicenter, randomized, double-blind, placebo-controlled study 2008 · Pycnogenol group · Women aged 18–48 years with low menstrual pain or dysmenorrhea | 60 mg | — | — |
| Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation 2008 · Pycnogenol · Adults with type 2 diabetes and mild to moderate hypertension, receiving ACE inhibitors | 125 mg | 12 weeks | — |
| Effect of French maritime pine bark extract supplementation on metabolic status and serum vascular cell adhesion molecule-1 levels in patients with type 2 diabetes and microalbuminuria 2021 · PBE group · Patients aged 30–65 years with type 2 diabetes and microalbuminuria | 100 mg | 8 weeks | — |
| Oral administration of French maritime pine bark extract (Flavangenol(®)) improves clinical symptoms in photoaged facial skin 2012 · Group 2, low-dose PBE treatment phase · Healthy women with age spots and mild-to-moderate facial photodamage | 40 mg | 12 weeks | 39 |
| Oral administration of French maritime pine bark extract (Flavangenol(®)) improves clinical symptoms in photoaged facial skin 2012 · Group 1, low-dose PBE · Healthy women with age spots and mild-to-moderate facial photodamage | 40 mg | 24 weeks | 38 |
| Oral administration of French maritime pine bark extract (Flavangenol(®)) improves clinical symptoms in photoaged facial skin 2012 · Part 2 long-term PBE participants · Healthy women with age spots and mild-to-moderate facial photodamage who completed the low-dose study | 40 mg | 1 year | 24 |
| The effect of antioxidant supplementation on fatigue during exercise: potential role for NAD+(H) 2010 · SUPPL (Lactaway) · Healthy trained and untrained males; trained cyclists or triathletes and untrained men from the general population, mean ages 30 and 29 years, respectively | 360 mcg | 1 day | 13 |
| Treatment of ADHD with French maritime pine bark extract, Pycnogenol 2006 · Pycnogenol · Children with ADHD; ages and sex not stated | 1 mg/kg | 4 weeks | — |
| Effect of a polyphenol-rich dietary supplement containing Pinus massoniana bark extract on blood pressure in healthy adults: A parallel, randomized placebo-controlled trial 2022 · PMBE group · Healthy Australian adults aged 55–75 years | 1.32 g | 12 weeks | — |
| Oral Pycnogenol® Intake Benefits the Skin in Urban Chinese Outdoor Workers: A Randomized, Placebo-Controlled, Double-Blind, and Crossover Intervention Study 2021 · Pycnogenol® intake · Han Chinese outdoor workers in Beijing; age and sex not specified | 100 mg | 12 weeks | 76 |
| Oligopin® Supplementation Mitigates Oxidative Stress in Postmenopausal Women with Osteopenia: A Randomized, Double-blind, Placebo-Controlled Trial 2021 · Oligopin® · Postmenopausal women with osteopenia | 150 mg | 12 weeks | 22 |
| Effects of French maritime pine bark extract (Oligopin®) supplementation on bone remodeling markers in postmenopausal osteopenic women: A randomized clinical trial 2019 · FMPBE · Postmenopausal women with osteopenia | 250 mg | 12 weeks | 21 |
| Distribution of Constituents and Metabolites of Maritime Pine Bark Extract (Pycnogenol(®)) into Serum, Blood Cells, and Synovial Fluid of Patients with Severe Osteoarthritis: A Randomized Controlled Trial 2017 · Pycnogenol group · Patients with severe osteoarthritis scheduled for elective knee replacement; mean age 64.3 years, both sexes | 100 mg | 3 weeks | 16 |
| Cellular pharmacodynamic effects of Pycnogenol® in patients with severe osteoarthritis: a randomized controlled pilot study 2017 · Pycnogenol® group · Adults with severe knee osteoarthritis (Kellgren-Lawrence grade III–IV) scheduled for elective arthroplasty; mean age about 64 years, women and men | 200 mg | 3 weeks | 16 |
| Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients 2004 · Pycnogenol group · Patients with hypertension | 100 mg | 12 weeks | — |
| Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study 2006 · Pycnogenol 150 mg daily · Patients with severe chronic venous insufficiency, venous hypertension, ankle swelling, and previous venous ulcerations; age and sex not reported | 150 mg | 8 weeks | — |
| Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study 2006 · Pycnogenol 300 mg daily · Patients with severe chronic venous insufficiency, venous hypertension, ankle swelling, and previous venous ulcerations; age and sex not reported | 300 mg | 8 weeks | — |
| The effect of French maritime pine bark extract supplementation on inflammation, nutritional and clinical status in critically ill patients with traumatic brain injury: A randomized controlled trial 2021 · intervention group · Critically ill patients with traumatic brain injury admitted to intensive care units; age and sex not stated | 150 mg | 10 days | — |
| A controlled study shows daily intake of 50 mg of French Pine Bark Extract (Pycnogenol®) lowers plasma reactive oxygen metabolites in healthy smokers 2013 · Pycnogenol group · Healthy cigarette smokers | 50 mg | 8 weeks | 78 |
| Effects of French Pine Bark Extract Chewing Gum on Oral Malodor and Salivary Bacteria 2018 · PYC gum · Healthy adults aged 40.1 ± 12.3 years with threshold breath sulfur compounds | 15 mg | 4 weeks | — |
| Circulating levels of reactive oxygen species in patients with nonproliferative diabetic retinopathy and the influence of antioxidant supplementation: 6-month follow-up 2015 · Group A (antioxidant dietary supplementation) · Adults aged 40–79 with type 2 diabetes and mild or moderate nonproliferative diabetic retinopathy | 50 mg | 26 weeks | 34 |